13F-NT: Royalty Pharma Files 13F-NT for Q4 2025
Institutional Holdings Notice
Royalty Pharma plc filed a 13F-NT notice for the quarter ended December 31, 2025, indicating its holdings are reported by a sub-manager.
Summary
- Royalty Pharma plc submitted a Form 13F-NT for the calendar quarter ending December 31, 2025.
- This filing is designated as a '13F NOTICE', signifying that Royalty Pharma plc itself is not reporting any holdings in this specific document.
- All institutional investment holdings for Royalty Pharma plc are reported by another designated manager, specifically Royalty Pharma Sub-Manager, LLC.
- The report was signed by Jason Mehar, SVP, Investments & Deputy General Counsel, on April 1, 2026, in New York, NY.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard administrative notice (13F-NT) indicating that holdings are reported by a sub-manager, rather than a report on financial performance or strategic changes.
Management Comments
- The person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.
Industry Context
StockSavvy.ai notes that 13F-NT filings are standard for institutional investment managers who delegate the reporting of their holdings to sub-managers, ensuring transparency in the market regarding significant equity positions without duplicating reported data.
Related Party Transactions
- Royalty Pharma Sub-Manager, LLC is reporting institutional investment holdings on behalf of Royalty Pharma plc, indicating a related party relationship for regulatory reporting purposes.
Stakeholder Impact
- Shareholders: Provides clarity on the reporting structure for institutional holdings, confirming compliance with SEC regulations.
- Regulatory Authorities: Fulfills the mandatory SEC reporting requirements for institutional investment managers.
Key Dates
| Date | Description |
|---|---|
| 12-31-2025 | Calendar Year or Quarter Ended for the report. |
| 04-01-2026 | Date the report was signed by Jason Mehar. |
Keywords
Royalty Pharma, 13F-NT, SEC Filing, Institutional Investment, Holdings Report, Investment Manager
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.